# Veterinary Biologics Market > Veterinary Biologics Market Research Report By Type (Vaccines, Antibiotics, Antiparasitics, Growth Promoters), By Species (Livestock, Companion Animals), By Target Disease (Bacterial Infections, Viral Infections, Parasitic Infections, Metabolic Disorders), By Source (Cell Culture, Inactivated Pathogens, Recombinant Technologies), By Application (Disease Prevention, Disease Treatment, Growth Promotion) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.31% - **2024:** $ 27.58 Billion - **2025:** $ 28.77 Billion - **2035:** $ 43.88 Billion - **Key Players:** Zoetis(US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Virbac (FR), Ceva Santé Animale (FR), Heska Corporation (US), Vetoquinol (FR), Phibro Animal Health (US).Companies such as Zoetis continue to expand portfolios including zoetis dog vaccines, while Elanco strengthens workforce capability through initiatives like elanco veterinary medical applications certification. **Report ID:** MRFR/HC/26269-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/veterinary-biologics-market-27956 --- ## Market Summary ## **Veterinary Biologics Market Overview** As per MRFR analysis, the Veterinary Biologics Market Size was estimated at 27.58 (USD Billion) in 2024. The Veterinary Biologics Market Industry is expected to grow from 28.77 (USD Billion) in 2025 to 42.07 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.31% during the forecast period (2025 - 2034). ## **Key Veterinary Biologics Market Trends Highlighted** The market for veterinary biologics is primarily driven by rising pet ownership, rising animal health awareness, and the rise in infectious illness prevalence in animals. Possibilities include growing into emerging markets and creating innovative treatments, diagnostics, and vaccinations. Personalized medicine, recombinant DNA technologies, and the growth of pet insurance are examples of recent trends. Growing awareness of animal health and welfare, increasing research and development, and technological developments are some of the reasons driving the predicted considerable rise in the market in the upcoming years. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Veterinary Biologics Market Drivers** ### Increasing Prevalence of Animal Diseases The escalating prevalence of animal diseases is one of the most significant factors propelling the growth of the Veterinary Biologics Market. Climate change and intensive animal farming practices, as well as increased global trade in animals and animal products, have facilitated the spread of diseases. Veterinary biologics, such as vaccines, antisera, and diagnostics, are essential for the prevention, control, and eradication of these diseases, thereby safeguarding animal health and welfare. Consequently, the demand for veterinary biology is bound to increase with the escalating prevalence of animal diseases. ### Growing Demand for Pet Healthcare The increasing popularity of companion animals and the growing awareness of their health and well-being are driving the demand for veterinary biology. Pet owners are becoming more proactive in seeking preventive care for their pets, including vaccinations and regular check-ups. This has led to a surge in the demand for veterinary biologics, particularly vaccines and diagnostics, as pet owners seek to protect their furry companions from diseases and ensure their longevity. ### Technological Advancements Advancements in biotechnology and genetic engineering have revolutionized the development and production of veterinary biologics. Recombinant DNA technology, monoclonal antibodies, and gene editing techniques have enabled the creation of more effective and targeted vaccines, diagnostics, and therapeutics. These advancements have improved the specificity, potency, and safety of veterinary biologics, enhancing their ability to prevent and treat animal diseases. ## **Veterinary Biologics Market Segment Insights** ### **Veterinary Biologics Market Type Insights** The veterinary biologics market is classified into four main types. These include vaccines, antibiotics, antiparasitics, and growth promoters, which have different characteristics and uses. Vaccines are developed to prevent or cure different diseases in animals by stimulating the immune system to fight off antigens or pathogens. Antibiotics are used to cure bacterial attacks in different body parts. Antiparasitics are used to prevent parasitic infection in animals by killing or keeping them off the animals. Growth promoters are used to increase the rate of growth and fattening of animals. The Veterinary Biologics Market is expected to witness growth in both developed and developing countries. Vaccines were the largest segment of the market, accounting for over 50% of the total revenue in 2023. The increasing adoption of vaccines to protect animals against different infections is one of the factors that will propel the growth of this segment. Antibiotics was the second-largest segment of the market, accounting for over 25% of the total revenue in 2023. The increasing use of antibiotics to cure different animal diseases is one of the drivers that will increase this segment. Antiparasitics was the third-largest segment of the market, accounting for over 15% of the total revenue in 2023. The use of antiparasitics to prevent parasites that affect animals is one of the factors that will increase this segment. Growth promoters were the smallest segment of the market, accounting for less than 10% of the total revenue in 2023. The increasing demand for animal proteins in many countries will also increase the growth of this segment. The Veterinary Biologics Market is highly competitive, with many large and small players. Some of the key players in the market are as follows: Merck Co., Inc., Zoetis Inc., Boehringer Ingelheim, Virbac, and Ceva Animal Health. These companies are investing heavily in research and development to develop new and innovative products. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Veterinary Biologics Market Species Insights** The Veterinary Biologics Market is divided by species into livestock and companion animals. The livestock segment dominated the segment in terms of market share in 2023, and it is expected to continue its dominance during the forecast period. The growth of the livestock segment can be attributed to the increasing need for animal protein, the prevalence of animal diseases, and the growing adoption of vaccination programs. The companion animal segment is expected to grow at a steady rate in the forthcoming years. Pet ownership and the increased awareness of pet health are contributing to the growth of the companion animal segment. The Veterinary Biologics Market for livestock will have a value of USD 18.54 billion by 2032 and will exhibit a CAGR of 4.0% during the forecast period. The Veterinary Biologics Market for companion animals will have a value of USD 18.53 billion by 2032 and will exhibit a CAGR of 4.6% during the forecast period. ### **Veterinary Biologics Market Target Disease Insights** Bacterial infections were the leading target disease for veterinary biologics, accounting for a global market revenue of USD 10.23 billion in 2023. The high prevalence of bacterial diseases in livestock, such as bovine respiratory disease complex and porcine reproductive and respiratory syndrome, drives the demand for vaccines and other biologics to prevent and treat these infections. Viral infections are another significant target disease, with a market size of USD 8.76 billion in 2023. The rising incidence of parasitic diseases in animals, coupled with the increasing adoption of companion animals, is fueling the growth of this market. Metabolic disorders are also a key target disease for veterinary biologics, with the market worth USD 4.87 billion in 2023. The increasing prevalence of obesity and other metabolic disorders in pets is driving the demand for biologics to manage and treat these conditions. ### **Veterinary Biologics Market Source Insights** The Veterinary Biologics Market is segmented based on source, which includes cell culture, inactivated pathogens, and recombinant technologies. Cell culture held the largest share of the market in 2023 and is expected to continue to dominate during the forecast period, owing to the increasing use of cell-based vaccines and therapeutics. The inactivated pathogens segment is also expected to witness significant growth, as these vaccines are cost-effective and have a proven track record of safety and efficacy. Recombinant technologies offer advantages such as high specificity, purity, and consistency and are expected to gain traction in the coming years. The market growth is attributed to the increasing prevalence of animal diseases, rising demand for preventive healthcare measures, and technological advancements. ### **Veterinary Biologics Market Application Insights** The Veterinary Biologics Market is segmented by Application into Disease Prevention, Disease Treatment, and Growth Promotion. Among these, the Disease Prevention segment accounted for the largest revenue share in 2023 and is projected to maintain its dominance throughout the forecast period. This is primarily attributed to the increasing adoption of preventive measures by animal owners to safeguard their livestock from diseases. The Disease Treatment segment is expected to witness significant growth over the forecast period, owing to the rising prevalence of animal diseases and the increasing demand for effective treatment options. The Growth Promotion segment is also anticipated to experience steady growth, driven by the demand for biologics that enhance animal growth and productivity. ### **Veterinary Biologics Market Regional Insights** The regional landscape of the Veterinary Biologics Market exhibits significant growth opportunities across various regions. North America held a dominant position in the market in 2023, capturing around 40% of the global revenue share. The region's well-established veterinary infrastructure, high pet ownership rates, and advanced animal healthcare practices contribute to its market dominance. Europe follows closely, accounting for approximately 30% of the market share. The region's stringent regulatory framework, focus on animal welfare and presence of major pharmaceutical companies drive its market growth. The Asia-Pacific (APAC) region is poised for substantial growth in the coming years, with a projected CAGR of 6.2% during the forecast period (2024-2032). Growing pet ownership, rising disposable income, and increasing awareness about animal health in countries like China, India, and Japan are key factors fueling the market expansion in APAC. South America and the Middle East and Africa (MEA) regions are also expected to witness steady growth, driven by government initiatives to improve animal health and increasing investments in veterinary infrastructure. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Veterinary Biologics Market Key Players and Competitive Insights** Major competitors in the veterinary biologics market are continuously trying to expand their market share and improve their competitive position. These companies are focused on research and development of innovative products to cater to the changing needs of the market. Moreover, leading competitors in the veterinary biologics market are entering into acquisitions and mergers to enrich their product portfolios. In the coming years, veterinary biologics market is expected to grow at a rapid pace on account of presence of several driving factors such as increasing population of animals, growing demand for animal protein, and ever-widening awareness about animal health. The veterinary biologics market Competitive Landscape is an intense market as major competitors are trying to enhance their market share. Zoetis is one of the key players in Veterinary Biologics Market. The company had a strong R focus and a diverse set of products. Formerly a part of Pfizer, Zoetis has a vast network of distributors and customers all around the world. The company’s core strength lies in developing and selling parasiticides, vaccines, and other animal health products. In addition, Zoetis is a pioneer in using new technologies as the company is actively involved in developing recombinant vaccines, monoclonal antibodies, and DNA vaccines. Lastly, Zoetis is a highly acquisitive company and is actively using acquisitions and partnerships to complement its product lines. Another prominent Veterinary Biologics Market competitor is Merck Animal Health. It is also a research and production-focused company with a number of innovative products such as recombinant vaccines, monoclonal antibodies, and DNA vaccines. The company has a vast network of distributors and customers around the world. Moreover, Merck Animal Health is actively acquisitive, which means it is always in the search for companies or products that will complement its existing products or fill a major gap in the portfolio. ### **Key Companies in the veterinary biologics market Include** ## **Veterinary Biologics Market Developments** The Veterinary Biologics Market is poised to grow significantly in the coming years, driven by rising pet ownership, increasing awareness of animal health, and technological advancements in vaccine development. Recent developments in the market include the launch of new vaccines for animal diseases such as African swine fever and avian influenza, as well as the increasing adoption of personalized medicine approaches to animal healthcare. Key players in the market are investing in research and development to expand their product portfolios and enhance the efficacy of their biologics. Strategic collaborations and acquisitions are also shaping the competitive landscape as companies seek to strengthen their market positions and gain access to new technologies. ## **Veterinary Biologics Market Segmentation Insights** ### **Veterinary Biologics Market Type Outlook** ### **Veterinary Biologics Market Species Outlook** ### **Veterinary Biologics Market Target Disease Outlook** ### **Veterinary Biologics Market Source Outlook** ### **Veterinary Biologics Market Application Outlook** ### **Veterinary Biologics Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Rising Animal Health Awareness The Veterinary Biologics Market is experiencing a notable surge in demand due to increasing awareness regarding animal health among pet owners and livestock producers. This heightened consciousness is largely driven by the growing recognition of the importance of preventive healthcare measures, including vaccinations and biologics.   As a result, the market for veterinary biologics is projected to expand significantly, with estimates suggesting a compound annual growth rate of approximately 7% over the next few years. This trend indicates that stakeholders in the Veterinary Biologics Market must adapt to evolving consumer preferences, focusing on innovative solutions that enhance animal welfare and health outcomes. ### Increasing Livestock Production The demand for veterinary biologics is closely linked to the rising need for livestock production to meet global food demands. As the population continues to grow, the pressure on livestock producers to enhance productivity and ensure animal health intensifies. This trend is driving the Veterinary Biologics Market, as producers increasingly rely on vaccines and biologics to prevent diseases and improve overall herd health.   The market is projected to grow at a rate of approximately 5% annually, reflecting the critical role that biologics play in maintaining livestock health and productivity. Consequently, stakeholders must focus on developing biologics that address the specific health challenges faced by livestock. ### Regulatory Support for Biologics The Veterinary Biologics Market is benefiting from a favorable regulatory environment that encourages the development and approval of new biologics. Regulatory agencies are increasingly recognizing the importance of biologics in animal health, leading to streamlined approval processes and guidelines that facilitate market entry. This supportive framework is crucial for fostering innovation and ensuring that veterinarians have access to safe and effective biologics.   As a result, the market is expected to witness a steady influx of new products, contributing to an anticipated growth rate of around 6% annually. Stakeholders in the Veterinary Biologics Market must remain vigilant in navigating regulatory changes to capitalize on emerging opportunities. ### Advancements in Biologics Technology Technological innovations are playing a pivotal role in shaping the Veterinary Biologics Market. The development of novel biologics, including vaccines and monoclonal antibodies, is enhancing the efficacy and safety of animal health products. Recent advancements in biotechnology, such as recombinant DNA technology and genomics, are enabling the creation of more targeted and effective biologics.   This evolution is expected to drive market growth, with the veterinary biologics segment projected to reach a valuation of over USD 10 billion by 2026. Consequently, companies operating within the Veterinary Biologics Market are likely to invest heavily in research and development to stay competitive and meet the increasing demand for advanced animal health solutions. ### Emerging Markets and Veterinary Services The Veterinary Biologics Market is witnessing growth in emerging markets, where increasing disposable incomes and urbanization are driving demand for veterinary services. As pet ownership rises and livestock farming becomes more commercialized, the need for effective biologics is becoming more pronounced.   This trend is expected to result in a market expansion of around 8% in these regions, as stakeholders seek to provide comprehensive health solutions for animals. Companies in the Veterinary Biologics Market should consider tailoring their products and services to meet the unique needs of these emerging markets, ensuring that they remain competitive in a rapidly evolving landscape. ## Future Outlook The Veterinary Biologics Market size is projected to reach USD 43.88 Billion by 2035, growing at a CAGR of 4.31%, driven by increasing pet ownership, advancements in biotechnology, and rising demand for preventive care. **New opportunities:** - Development of personalized vaccines for companion animals Expansion of biologics in aquaculture for disease management Integration of telemedicine for remote diagnostics and treatment By 2035, the Veterinary Biologics Market is expected to be robust, reflecting sustained growth and innovation. ## Segment Insights ### By Type: Vaccines (Largest) vs. Antibiotics (Fastest-Growing) In the Veterinary Biologics Market, vaccines dominate the 'Type' segment, comprising the largest market share. This is largely due to the increasing awareness and importance of preventive healthcare for pets and livestock, leading to a higher uptake of vaccination programs, including **zoetis dog vaccines**. Antibiotics, while holding a smaller share, are witnessing rapid growth driven by an increasing incidence of bacterial infections in animals and a rising trend toward meat and dairy production, necessitating effective antibiotic solutions. Vaccines (Dominant) vs. Antibiotics (Emerging) Vaccines are recognized as the dominant segment within the Veterinary Biologics Market due to their critical role in preventing diseases, thereby ensuring the health and productivity of animals. They are characterized by a variety of formulations, including live-attenuated, inactivated, and recombinant vaccines. On the other hand, antibiotics are emerging as a crucial segment, experiencing significant demand due to rising concerns regarding animal health and the efficient production of animal-derived products. The antibiotic segment is evolving to focus on more responsible usage and development of new formulations to combat antibiotic resistance, reflecting a shift towards sustainable practices in veterinary care. ### By Species: Companion Animals (Largest) vs. Livestock (Fastest-Growing) In the Veterinary Biologics Market, the distribution of market share among different species reveals that Companion Animals hold a predominant position. This segment caters to pets such as cats and dogs and is supported by advanced diagnostics, veterinary hospitals, and **animal care and equipment** ecosystems. Awareness of treatment outcomes, including monitoring **side effects to cytopoint**, further supports biologics adoption. The focus on preventative health, alongside a robust consumer base willing to invest in pet care, solidifies this segment's largest market share in the industry. On the other hand, the Livestock segment, encompassing animals like cattle, pigs, and poultry, while smaller in share, is rapidly gaining traction. Factors such as increasing awareness regarding animal health, disease outbreaks, and the nutritional needs of livestock contribute to its growth trajectory. Companion Animals (Dominant) vs. Livestock (Emerging) The Companion Animals segment in the market share is characterized by an expanding array of vaccines, diagnostics, and treatments specifically designed to enhance pet health and wellbeing. The segment has witnessed significant innovation fueled by the humanization of pets, with owners increasingly seeking high-quality healthcare products for their animals. In contrast, the Livestock segment is emerging, driven by evolving agricultural practices and heightened focus on animal welfare. This segment aims to mitigate disease risks and enhance productivity through advanced biologics tailored for larger herds. While livestock products may not command as significant a market share currently, their growth is underpinned by the rising demand for sustainable farming, which further propels research and development in this area. ### By Target Disease: Bacterial Infections (Largest) vs. Viral Infections (Fastest-Growing) In the Veterinary Biologics Market, Bacterial Infections hold the largest share due to the prevalence of various bacterial pathogens affecting livestock and pets. This segment has been a cornerstone in the development of vaccines and treatment modalities, with comprehensive diagnostics and therapeutics tailored specifically for bacterial pathogens. On the other hand, Viral Infections are emerging rapidly, indicated by significant advancements in vaccine development and therapy options. The focus on preventive measures against viral outbreaks in both farm and companion animals reflects the growing awareness and demand in this area. Bacterial Infections (Dominant) vs. Viral Infections (Emerging) Bacterial Infections represent a dominant force in the market share, driven by a well-established portfolio of vaccines designed to combat leading bacterial diseases. The segment encompasses various species, including dogs, cats, cattle, and poultry, ensuring broad market engagement. In contrast, Viral Infections are emerging, spurred by the increasing incidence of viral diseases and the subsequent demand for innovative vaccine solutions. The growth in this segment is fueled by advancements in biotechnology and an enhanced understanding of viral pathogenesis, leading to more effective targeting of vaccine development. As the landscape evolves, a focus on both segments highlights the critical balance needed to support animal health. ### By Source: Cell Culture (Largest) vs. Recombinant Technologies (Fastest-Growing) In the Veterinary Biologics Market, the source segment is primarily characterized by its diverse methodologies, with Cell Culture holding the largest market share. This segment capitalizes on the traditional approaches utilized for vaccine development, proving to be a backbone for the production of effective biologicals. Inactivated Pathogens also contribute significantly to the share, leveraging established practices in pathogen control. Meanwhile, Recombinant Technologies are gaining traction and represent an innovative shift, reflecting the segment's ongoing evolution and adaptation in veterinary applications. Cell Culture (Dominant) vs. Recombinant Technologies (Emerging) Cell Culture remains the dominant method in the market share, celebrated for its long-standing effectiveness in producing vaccines and therapeutic products. It enables the generation of high-quality biologicals by culturing cells in a controlled environment. Conversely, Recombinant Technologies, while emerging, are showcasing transformative potential, utilizing genetic engineering techniques to create vaccines that are more specific and effective. This method appeals due to its precision and the capacity to rapidly innovate in response to emerging pathogens, thereby meeting evolving market demands. ### By Application: Disease Prevention (Largest) vs. Disease Treatment (Fastest-Growing) In the Veterinary Biologics Market, the application segment is predominantly represented by Disease Prevention, which commands a significant share thanks to its crucial role in safeguarding animal health. As the need for preventive measures against infectious diseases rises, this segment continues to dominate, capturing attention from veterinarians and livestock producers alike. Following closely is the Disease Treatment segment, aimed at addressing existing health issues, reflecting a growing awareness of animal welfare and optimal health management practices among pet owners and livestock operators. Disease Prevention (Dominant) vs. Disease Treatment (Emerging) Disease Prevention stands as the dominant force in the market share, characterized by a strong focus on proactive measures to ensure animal health. This segment includes vaccines and immunization products, which are essential in preventing disease outbreaks in both companion animals and livestock. On the other hand, Disease Treatment is emerging with innovative therapeutic solutions aimed at effectively managing and curing ailments in animals. Driven by advancements in veterinary medicine and increasing investments in research, this segment is witnessing rapid growth as more products become available to treat a variety of health conditions. The interplay between these segments highlights an increasingly dual approach to animal healthcare, emphasizing the importance of both prevention and treatment. ## Regional Market Share Analysis ### North America : Market Leader in Biologics North America leads in the Veterinary Biologics Market Size, accounting for over 44.96% of the global revenue in 2024. The region's growth is driven by increasing pet ownership, rising awareness of animal health, and advanced diagnostics platforms such as idexx imaging. The demand for vaccines and diagnostics is particularly strong, supported by advancements in biotechnology and a robust healthcare infrastructure. The United States is the leading country in this market, with major players like Zoetis, Merck Animal Health, and Elanco Animal Health dominating the landscape. Canada also contributes significantly, focusing on innovative solutions for livestock and companion animals. The competitive environment is characterized by continuous R&D investments and strategic partnerships among key players, enhancing product offerings and market reach. ### Europe : Regulatory Frameworks Drive Growth Europe Veterinary Biologics Market was valued at USD 8.27 billion in 2024, making it the second-largest regional market with a 30% share. The region benefits from stringent regulatory frameworks that promote high standards for animal health products. Increasing consumer awareness regarding animal welfare and the rising prevalence of zoonotic diseases are key drivers of market growth. Additionally, the European Union's initiatives to support sustainable agriculture are catalyzing demand for innovative biologics. Leading countries in this region include Germany, France, and the UK, where companies like Boehringer Ingelheim and Virbac are prominent. The competitive landscape is marked by a mix of established firms and emerging biotech companies, focusing on developing novel vaccines and therapeutics. The presence of strong regulatory bodies ensures that products meet rigorous safety and efficacy standards, fostering consumer trust and market expansion. ### Asia-Pacific : Rapid Growth in Emerging Markets Asia-Pacific is witnessing rapid growth in the veterinary biologics market, accounting for approximately 20% of the global share. The region's expansion is fueled by increasing livestock production, rising pet ownership, and growing awareness of animal health. Countries like China and India are leading this growth, supported by government initiatives aimed at enhancing animal health standards and food safety regulations. China is the largest market in the region, with significant investments in veterinary research and development. The competitive landscape features both local and international players, including Ceva Santé Animale and Heska Corporation. The region is characterized by a diverse range of products, from vaccines to diagnostics, catering to both livestock and companion animals. The increasing focus on biosecurity measures is further driving demand for effective veterinary biologics. ### Middle East and Africa : Emerging Market Potential The Middle East and Africa (MEA) region is gradually emerging as a potential market for veterinary biologics, holding about 5% of the global share. The growth is driven by increasing livestock farming, rising pet ownership, and a growing awareness of animal health issues. Regulatory bodies in various countries are beginning to implement stricter guidelines, which is expected to enhance product quality and safety in the market. Leading countries in this region include South Africa and the UAE, where there is a growing demand for vaccines and diagnostics. The competitive landscape is still developing, with both local and international companies vying for market share. Key players are focusing on expanding their product portfolios and establishing distribution networks to tap into the growing demand for veterinary biologics in this region. ## Competitive Benchmarking The Veterinary Biologics Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for animal health products and a growing focus on preventive care. Key players such as Zoetis (US), Merck Animal Health (US), and Boehringer Ingelheim (DE) are strategically positioned to leverage innovation and expand their product portfolios. Zoetis continues to strengthen its leadership in companion animal health through vaccine innovation, including zoetis dog vaccines, while Elanco emphasizes professional development through initiatives such as elanco veterinary medical applications certification. Boehringer Ingelheim (DE) appears to prioritize sustainability and digital transformation, integrating advanced technologies into its operations. Collectively, these strategies not only enhance their competitive edge but also shape the overall market dynamics, fostering a climate of innovation and collaboration. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Veterinary Biologics Market is moderately fragmented, with a mix of large multinational corporations and smaller specialized firms. This structure allows for diverse offerings and competitive pricing, yet the influence of key players remains substantial, as they set industry standards and drive technological advancements. In August 2025, Zoetis (US) announced the launch of a novel vaccine targeting a prevalent infectious disease in livestock, which is expected to significantly enhance animal health outcomes. This strategic move not only reinforces Zoetis's commitment to innovation but also positions the company to capture a larger market share in the livestock sector.   The introduction of this vaccine is likely to address critical health challenges faced by farmers, thereby strengthening Zoetis's reputation as a leader in veterinary biologics. In September 2025, Merck Animal Health (US) expanded its collaboration with a leading biotechnology firm to develop next-generation biologics aimed at improving animal welfare. This partnership underscores Merck's strategy to integrate cutting-edge technology into its product development pipeline. By focusing on welfare-enhancing solutions, Merck is not only responding to consumer demands but also aligning with global trends towards more humane animal treatment, which could enhance its market position. In July 2025, Boehringer Ingelheim (DE) launched a digital platform designed to streamline veterinary practices and improve client engagement. This initiative reflects the company's commitment to digital transformation and its recognition of the growing importance of technology in veterinary care. By enhancing connectivity between veterinarians and pet owners, Boehringer Ingelheim is likely to foster loyalty and improve service delivery, thereby gaining a competitive advantage in the market.    As of October 2025, the Veterinary Biologics Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence into product development and customer engagement strategies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from traditional price-based competition towards innovation, technological advancements, and supply chain reliability. This transition may redefine market dynamics, compelling companies to invest in research and development to maintain their competitive edge. ## Recent News & Developments The Veterinary Biologics Market is poised to grow significantly in the coming years, driven by rising pet ownership, increasing awareness of animal health, and technological advancements in vaccine development. Recent developments include the launch of new vaccines, expanded biologics research collaborations with firms such as **asp global llc**, and increasing adoption of advanced diagnostics and biologics-supported therapeutics. Key players in the market are investing in research and development to expand their product portfolios and enhance the efficacy of their biologics. Strategic collaborations and acquisitions are also shaping the competitive landscape as companies seek to strengthen their market positions and gain access to new technologies. ## Report Scope | MARKET SIZE 2024 | 27.58(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 28.77(USD Billion) | | MARKET SIZE 2035 | 43.88(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.31% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Virbac (FR), Ceva Santé Animale (FR), Heska Corporation (US), Vetoquinol (FR), Phibro Animal Health (US) | | Segments Covered | Type, Species, Target Disease, Source, Application, Regional | | Key Market Opportunities | Advancements in personalized veterinary vaccines present a transformative opportunity in the Veterinary Biologics Market. | | Key Market Dynamics | Rising demand for innovative vaccines drives competitive dynamics in the Veterinary Biologics Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Veterinary Biologics Market as of 2024?** A: The Veterinary Biologics Market was valued at 27.58 USD Billion in 2024. **Q: What is the projected market size for the Veterinary Biologics Market in 2035?** A: The market is projected to reach 43.88 USD Billion by 2035. **Q: What is the expected CAGR for the Veterinary Biologics Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Veterinary Biologics Market during the forecast period 2025 - 2035 is 4.31%. **Q: Which segments are expected to show growth in the Veterinary Biologics Market?** A: Segments such as Vaccines and Companion Animals are expected to show notable growth. **Q: What are the key types of products in the Veterinary Biologics Market?** A: Key product types include Vaccines, Antibiotics, Antiparasitics, and Growth Promoters. **Q: How do the revenues from Livestock and Companion Animals compare in the market?** A: In 2024, revenues from Companion Animals were higher at 17.58 USD Billion compared to 10.0 USD Billion from Livestock. **Q: What are the leading companies in the Veterinary Biologics Market?** A: Key players include Zoetis, Merck Animal Health, and Boehringer Ingelheim. **Q: What are the primary target diseases addressed by Veterinary Biologics?** A: Primary target diseases include Viral Infections, Bacterial Infections, and Parasitic Infections. **Q: What sources are utilized in the production of Veterinary Biologics?** A: Sources include Cell Culture, Inactivated Pathogens, and Recombinant Technologies. **Q: What applications are driving the Veterinary Biologics Market?** A: Applications driving the market include Disease Prevention, Disease Treatment, and Growth Promotion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/veterinary-biologics-market-27956*